Ruxolitinib
JAKAFI, OPZELURA
Kinase Inhibitor
NADAC/unit
$34.1433
No Shortage
Tier 1: 89.7%
PA Req: 499.1%
Ruxolitinib targets specific kinase enzymes involved in cancer cell growth and proliferation.
vs. brand JAKAFI: Generic saves up to -241% per unit
Generic Manufacturers
INCYTE CORP
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.